Abbreviation and Acronyms

ACSM

Advocacy, Communication, and Social Mobilization

ACF

Active Case Finding

ACH

Air Changes per Hour

ADR

Adverse Drug Reaction

AFB

Acid-fast bacillus

AIC

Airborne Infection Control

AIDS

Acquired Immune Deficiency Syndrome

AMC

Annual Maintenance Contract

AMK

Amikacin

ART

Antiretroviral Therapy

ATT

Anti-tubercular Treatment

BCAP

Bedaquiline Conditional Access Programme

BCG

Bacille Calmette-Guerin

BDQ

Bedaquiline

BMI

Body Mass Index

BSC

Biological Safety Cabinet

C&DST

Culture and Drug Susceptibility Testing

CB-NAAT

Cartridge-based Nucleic Acid Amplification Test

CHW

Community Health Worker

CFZ

Clofazimine

CI

Contact Investigation

CME

Continuing Medical Education

CPT

Cotrimoxazole Preventive Therapy

CSO

Civil Society Organization

CXR

Chest X-Ray

DLM

Delamanid

DM

Diabetes Mellitus

DOT

Directly Observed Therapy

DOTS

Directly Observed Therapy, Short-course

DR-TB

Drug Resistant Tuberculosis

DRS

Drug Resistance Surveillance

DST

Drug Susceptibility Testing

DS-TB

Drug-Sensitive Tuberculosis

DQA

Data Quality Assurance

E

Ethambutol

EPTB

Extrapulmonary Tuberculosis

EQA

External Quality Assurance

FDC

Fixed-dose Combination

FLD

First-line Drugs

FQ

Fluoroquinolone

GDF

Global Drug Facility

GFATM

Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria

H

Isoniazid

HA

Health Assistant

HBC

High Burden Countries

HCW

Health Care Worker

HIV

Human Immunodeficiency Virus

HR

Human Resources

HS

Health Systems

HSS

Health Systems Strengthening

IC

Infection Control

ICF

Intensified Case Finding

ICT

Information and Communication Technologies

IEC

Information, Education, and Communication

IGRA

Interferon-Gamma Release Assay

INH

Isoniazid

IPC

Infection Prevention and Control

JMM

Joint Monitoring Mission

KPI

Key Performance Indicator

LFX

Levofloxacin

LPA

Line Probe Assay

LT

Laboratory Technician

LTBI

Latent Tuberculosis Infection

LTFU

Lost To Follow Up

LZD

Linezolid

M&E

Monitoring and Evaluation

MDG

Millennium Development Goal

MDR

Multidrug Resistance

MDR-TB

Multidrug Resistant Tuberculosis

MFX

Moxifloxacin

MGIT

Mycobacteria Growth Indicator Tube

MTB

Mycobacterium Tuberculosis

NCD

Noncommunicable Disease

NGO

Non-governmental Organization

NGS

Next-Generation Sequencing

NTRL

National TB Reference Laboratory

NSP

National Strategic Plan

NTM

Non-Tuberculous Mycobacteria

NTP

National Tuberculosis Control Programme

OR

Operational Research

PCR

Polymerase Chain Reaction

PICT

Provider Initiated Counseling and Testing

PLHIV

People Living with HIV/AIDS

PP

Private Practitioner

PPM

Public-Private Mix

PTB

Pulmonary Tuberculosis

QA

Quality Assurance

R / RIF

Rifampicin

RR-TB

Rifampicin-Resistant Tuberculosis

RTRL

Regional TB Reference Laboratory

SDG

Sustainable Development Goals

SEARO

South East Asia Regional Office

SLD

Second-line Drugs

SL-DST

Second-line Drug Susceptibility Testing

SLI

Second-line Injectable Drugs

SNRL

Supra National Reference Laboratory

TA

Technical Assistance

TAT

Turnaround Times

TALF

Treatment After Lost to Follow Up

TB

Tuberculosis

TLCA

TB and Leprosy Control Assistant

TOR

Terms of Reference

TPT

TB Preventive Treatment

TST

Tuberculin Skin Test

UDST

Universal Drug Susceptibility Tests

UN

United Nations

UNHLM

United Nations High-level Meeting

UVGI

Ultraviolet Germicidal Irradiation

WHO

World Health Organization

WRD

WHO Recommended Rapid Diagnostics

XDR-TB

Extensively Drug Resistant Tuberculosis

Z

Pyrazinamide